1. Ito, S., Koshino, A., Komura, M., Kato, S., Otani, T., Wang, C., Ueki, A., Takahashi, H., Ebi, M., Ogasawara, N., Tsuzuki, T., Kasai, K., Kasugai, K., Takiguchi, S., Takahashi, S., Inaguma, S.: Characterization of colorectal cancer by hierarchical clustering analyses of five immune cell markers. Pathol Int, 74:13-25, 2024.
2. Denda, Y., Matsuo, Y., Nonoyama, K., Murase, H., Kato, T., Hayashi, Y., Imafuji, H., Saito, K., Morimoto, M., Kato, H., Yoshida, M., Naitoh, I., Hayashi, K., Ogawa, R., Takahashi, H., Takiguchi, S.: Simultaneous presentation and resection of esophageal cancer and metastasis to the pancreas: A case report and literature review. Mol Clin Oncol, 20:2, 2024.
3. Komura, M., Wang, C., Ito, S., Kato, S., Ueki, A., Ebi, M., Ogasawara, N., Tsuzuki, T., Kasai, K., Kasugai, K., Takiguchi, S., Takahashi, S., Inaguma, S.: Simultaneous expression of CD70 and POSTN in cancer-associated fibroblasts, predicts worse survival of colorectal cancer patients. Int J Mol Sci, 25:2537, 2024.
4. Morikawa, T., Iwatsuki, S., Naiki-Ito, A., Gonda, M., Taguchi, K., Naiki, T., Hamamoto, S., Okada, A., Yasui, T.: Urothelial carcinoma occurring in a defunctionalized bladder after urinary diversion due to the bladder exstrophy-epispadias complex. IJU Case Rep, 7:101-104, 2024.
5. Aoki, M., Naiki, T., Naiki-Ito, A., Morikawa, T., Matsuyama, N., Torii, K., Kato, T., Maruyama, T., Inaguma, S., Yasui, T.: Successful treatment with enfortumab-vedotin of metastatic signet ring cell cancer expressing nectin-4 and originating from the bladder. IJU Case Rep, 7:110-114, 2024.
6. Morikawa, T., Naiki, T., Sugiyama, Y., Naiki-Ito, A., Nagai, T., Etani, T., Iida, K., Isobe, T., Noda, Y., Shimizu, N., Aoki, M., Gonda, M., Banno, R., Kubota, H., Ando, R., Umemoto, Y., Kawai, N., Yasui, T.: C-reactive protein is a potential prognostic marker in patient with advanced or metastatic urothelial carcinoma treated with enfortumab vedotin: A multi-center retrospective study. Cancers, 16:1725, 2024.
7. Uno, K., Shimura, R., Inaguma, S., Kuroyanagi, K., Nishigaki, R., Kannno, T., Sasaki, M., Fukusada, S., Sugimura, N., Mizuno, Y., Nukui, T., Kojima, Y., Tanaka, M., Ozeki, K., Kubota, E., Takahashi, S., Kataoka, H.: Clinical impact of proton pump inhibitor and potassium-competitive acid blocker for predicting the curability of endoscopic resection in ulcerative early gastric cancer. Digestion, 105:192-200, 2024.
8. Hori, Y., Naitoh, I., Naiki-Ito, A., Kawai, T., Yoshida, M., Kato, A., Kachi, K., Sahashi, H., Adachi, A., Toyohara, T., Kito, Y., Yamamoto, T., Takahashi, S., Kataoka, H.: Incidence of pancreatic injury and pancreatitis in patients treated with immune checkpoint inhibitors. Clin Transl Gastroenterol, 15:e00667, 2024.
9. Ito, S., Koshino, A., Komura, M., Otani, T., Wang, C., Ueki, A., Kato, S., Takahashi, H., Ebi, M., Ogasawara, N., Tsuzuki, T., Kasai, K., Kasugai, K., Takiguchi, S., Takahashi, S., Inaguma, S.: Characterization of colorectal cancer by hierarchical clustering analyses for five stroma-related markers. J Pathol Clin Res, 10:e12386, 2024.
10. Hori, Y., Kawai, T., Naiki-Ito, A., Naitoh, I., Kato, A., Kataoka, H.: Asymptomatic pancreatic enlargement without pancreatic enzyme elevation: a rare case of immune checkpoint inhibitor-associated pancreatitis. Gastroenterol Rep, 2024：12, goae064, 2024.
11. Kato, H., Sato, M., Naiki-Ito, A., Inaguma, S., Sano, M., Komura, M., Nagayasu, Y., Xiaochen, K., Kato, A., Matsuo, Y., Ijichi, H., Takahashi, S.: The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer. Cancer Med, 13:e70124, 2024.
12. Kato, S., Koshino, A., Lasota, J., Komura, M., Wang, C., Ebi, M., Ogasawara, N., Kojima, K., Tsuzuki, T., Kasai, K., Takahashi, S., Miettinen, M., Kasugai, K., Inaguma, S.: Use of SATB2 and CDX2 immunohistochemistry to characterize and diagnose colorectal cancer. Appl Immunohistochem Mol Morphol, 32:362-370, 2024.
13. Naiki-Ito, A., Yeewa, R., Xiaochen, K., Taychaworaditsakul, W., Naiki, T., Kato, H., Nagayasu, Y., Chewonarin, T., Takahashi, S.: Hexane insoluble fraction from purple rice extract improves steatohepatitis and fibrosis via inhibition of NF-κB and JNK signaling, Food Funct, 15:8562-8571, 2024.
14. Inaguma, S., Wang, C., Ito, S., Ueki, A., Lasota, J., Czapiewski, P., Renata Langfort, R., Rys, J., Szpor, J., Waloszczyk, P., Okoń, K., Biernat, W., Takiguchi, S., Schrump, D.S., Miettinen, M., Takahashi, S.: Characterization of pleural mesothelioma by hierarchical clustering analyses using immune cells within tumor microenvironment. Pathobiology, 91:313-325, 2024.
15. Isobe, T., Naiki, T., Sugiyama, Y., Naiki-Ito, A., Nagai, T., Etani, T., Iida, K., Noda, Y., Shimizu, N., Aoki, M., Gonda, M., Morikawa, T., Banno, R., Kubota, H., Ando, R., Kawai, N., Yasui, T.: Experoence and prognostic analysis with avelumab switch maintenance treatment in metastatic urothelial carcinoma. Oncology, in press.
16. Sheema, A.N., Naiki-Ito, A., Kakehashi, A., Ahmed, O.H.M., Alexander, D.B., Alexander, W.T., Numano, T., Kato, H., Goto, Y., Takase, H., Hirose, A., Wakahara, T., Miyazawa, K., Takahashi, S., Tsuda, H.: Fullerene and fullerene whisker are not carcinogenic to the lungs and pleura in rat long-term study after intra-tracheal intrapulmonary administration. Arch Toxicol, 98:4143-4158, 2024.